OpGen to Provide Business Update and Financial Results for the Second Quarter 2021 on August 12th at 4:30 p.m. Eastern Time
OpGen, Inc. (NASDAQ: OPGN) will report its Q2 2021 financial results and provide a business update on August 12, 2021, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OpGen, Inc. (NASDAQ: OPGN) will report its Q2 2021 financial results and provide a business update on August 12, 2021, after U.S. market close. The management team will host a live conference call at 4:30 p.m. ET to discuss these results and business activities. Interested parties may join via the U.S. or International dial-in numbers provided or through a webcast link. A replay will be accessible until August 26, 2021. OpGen focuses on precision medicine and developing molecular diagnostics for infectious diseases to improve patient outcomes.
Details
News Market Reaction – OPGN
The recorded move for OPGN in the trading session of this news was -1.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2021 financial results after the close of the U.S. financial markets on Thursday, August 12, 2021. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.
| Conference Call Details | |
| U.S. Dial-in Number: | 1-800-458-4121 |
| International Dial-in Number: | 1-323-794-2093 |
| Webcast: | http://public.viavid.com/index.php?id=146054 |
| Conference ID: | 7301173 |
| Replay Details | |
| U.S. Dial-in Number: | 1-844-512-2921 |
| International Dial-in Number: | 1-412-317-6671 |
| Replay PIN: | 7301173 |
Following the conclusion of the conference call, a replay will be available through August 26, 2021. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website under Financials & Filings.
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas® AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.
For more information, please visit www.opgen.com.
OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com
OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com
OpGen Investor Contact:
Max Colbert
Edison Group
mcolbert@edisongroup.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.